When using evidence based analytics in decision making, measurement is an essential tool in gaging progress. However, the leader needs to assess data based on the following consideration(s). A) To what extent is the measurement an accurate representation of the success of the change initiative?
B) What is the relationship between the time of the measurement being reported and the timeframe over which the benefits of the change is expected to be delivered?
C) What are the components of the measurement being monitored e. g. internal and/or external environmental factors in to what extent are they relevant to the organizational change?

The development price itself is such a huge barrier, it's just a very different business model than boeing's used to. our huge development programs are typically centered around commercial airplanes, military aircraft, where there is a lot of orders. and right now the foundation of the business is two bites a year.

Trecek corporation incurs research and development costs of $625,000 in 2017, 30 percent of which relate to development activities subsequent to ias 38 criteria having been met that indicate an intangible asset has been created. the newly developed product is brought to market in january 2018 and is expected to generate sales revenue for 10 years. assume that a u.s.–based company is issuing securities to foreign investors who require financial statements prepared in accordance with ifrs. thus, adjustments to convert from u.s. gaap to ifrs must be made. ignore income taxes. required: (a) prepare journal entries for research and development costs for the years ending december 31, 2017, and december 31, 2018, under (1) u.s. gaap and (2) ifrs. (c) prepare the entry(ies) that trecek would make on the december 31, 2017, and december 31, 2018, conversion worksheets to convert u.s. gaap balances to ifrs.

On april 1, the cash account balance was $46,220. during april, cash receipts totaled $248,600 and the april 30 balance was $56,770. determine the cash payments made during april.